High-Concentration Antibody Formulations

Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals

Volumn , Issue , 2010, Pages 349-381

  Shire, Steven J ^a   Liu, Jun ^a   Friess, Wolfgang ^b   Jörg, Susanne ^c   Mahler, Hanns Christian ^d  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Formulation development and high concentration formulation approach; High concentration antibody formulations multiple advantages, for patients and health care systems; Robust manufacturing process design and implementation of benchtop experimental findings

Indexed keywords

EID: 79959949250     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470595886.ch15     Document Type: Chapter

References (92)

1. Shire, S. J. and Gombotz, W. (2010), in Current Trends in Monoclonal Antibody Development and Manufacturing, Shire, S. J., Gombotz, W., Bechtold-Peters, K., and Andya, J., eds., Springer, New York, pp. 1-5.
2. Pavlou, A. K. and Belsey, M. J. (2005), The therapeutic antibodies market to 2008, Eur. J. Pharm. Biopharm. 59(3): 389-396.
3. Roskos, L. K., Davis, C. G., and Schwab, G. M. (2004), The clinical pharmacology of therapeutic monoclonal antibodies, Drug Devel. Res. 61(3): 108-120.
4. Gatlin, L. A. and Gatlin, C. A. B. (1999), Formulation and administration techniques to minimize injection pain and tissue damage associated with parenteral products, in Injectable Drug Development: Techniques to Reduce Pain and Irritation, Gapta, P. K. and Brazeau, G. A., eds., Interpharm Press, Denver, pp. 401-425.
5. Chang, B. S. and Hershenson, S. (2002), Practical approaches to protein formulation development, in Rational Design of Stable Protein Formulations: Theory and Practice, Carpenter, J. F. and Manning, M. C., eds., Kluwer Academic/Plenum, New York, pp. 1-25.
6. Shire, S. J., Shahrokh, Z., and Liu, J., (2004), Challenges in the development of high protein concentration formulations, J. Pharm. Sci. 93(6): 1390-1402.
7. Harris, R. J., Shire, S. J., and Winter, C. (2004), Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies, Drug Devel. Res. 61(3): 137-154.
8. Porter, C., Edwards, G., and Charman, S. (2001), Lymphatic transport of proteins after s.c. injection: Implications of animal model selection, Adv. Drug Deliv. Rev. 50(1-2): 157-171.
9. Lobo, E. D., Hansen, R. J., and Balthasar, J. P. (2004), Antibody pharmacokinetics and pharmacodynamics, J. Pharm. Sci. 93(11): 2645-2668.
10. Schellekens, H. (2002), Bioequivalence and the immunogenicity of biopharmaceuticals, Nat. Rev. Drug Discov. 1(6): 457-462.
11. Klyushnichenko, V. (2003), Protein crystallization: from HTS to kilogram-scale, Curr. Opin. Drug Discov. Devel. 6(6): 848-854.
12. Bromberg, L., Rashba-Step, J., and Scott, T. (2005), Insulin particle formation in supersaturated aqueous solutions of poly(ethylene glycol), Biophys. J. 89(5): 3424-3433.
13. Schein, C. H. (1990), Solubility as a function of protein structure and solvent components, Bio/Technology 8(4): 308-317.
14. Shiloach, J., Martin, N., and Moes, H. (1988), Tangential flow filtration, Adv. Biotechnol. Processes 8: 97-125.
15. van Reis, R. and Zydney, A. (2001), Membrane separations in biotechnology, Curr. Opin. Biotechnol. 12(2): 208-211.
16. Gabler, F. (1987), Principles of tangential flow filtration: Applications to biological processing, in Filtration in the Pharmaceutical Industry, Meltzer, T., ed., Marcel Dekker, New York, pp. 453-488.
17. Thomas, C. R., Nienow, A. W., and Dunnill, P. (1979), Action of shear on enzymes: Studies with alcohol dehydrogenase, Biotechnol. Bioeng. 21(12): 2263-2278.
18. Watterson, J. G., Schaub, M. C., and Waser, P. G. (1974), Shear-induced protein-protein interaction at the air-water interface, Biochim. Biophys. Acta 356(2): 133-143.
19. Liu, J., Nguyen, M. D., Andya, J. D., and Shire, S. J. (2005), Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution, J. Pharm. Sci. 94(9): 1928-1940.
20. Masters, K. (1985), Spray Drying Handbook, 4th ed., Longman Scientific, New York.
21. Rouan, S. K. E. (1996), Biotechnology-based pharmaceuticals, in Modern Pharmaceutics, 3rd ed., Banker, G. S., and Rhodes, C. T., eds., Marcel Dekker, New York, pp. 843-873.
22. Sonner, C., Maa, Y. F., and Lee, G., (2002), Spray-freeze-drying for protein powder preparation: Particle characterization and a case study with trypsinogen stability, J. Pharm. Sci. 91(10): 2122-2139.
23. Poupitch, G. (1994), Fluid bed drying in the laboratory, Am. Biotechnol. Lab. 12(4): 30-34.
24. Wildfong, P. L., Samy, A. S., Corfa, J., Peck, G. E., and Morris, K. R. (2002), Accelerated fluid bed drying using NIR monitoring and phenomenological modelling: Method assessment and formulation suitability, J. Pharm. Sci. 91(3): 631-639.
25. Mattern, M., Winter, G., Kohnert, U., and Lee, G. (1999), Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems, Pharm. Devel. Technol. 4(2): 199-208.
26. Miller, D. P., Anderson, R. E., and de Pablo, J. J. (1998), Stabilization of lactate dehydrogenase following freeze thawing and vacuum-drying in the presence of trehalose and borate, Pharm. Res. 15(8): 1215-1221.
27. Avis, K. E. (1990), Parenteral preparations, in Remington's Pharmaceutical Sciences, 18th ed., Gennaro, A. R., ed., Mack Publishing, Easton, PA, pp. 1545-1569.
28. Schule, S., Schulz-Fademrecht, T., Garidel, P., Bechtold-Peters, K., and Friess, W., (2008), Stabilization of IgG1 in spray-dried powders for inhalation, Eur. J. Pharm. Biopharm. 69(3): 793-807.
29. Andya, J., Cleland, J., Hsu, C., Lam, X., Overcashier, D., Shire, S., Yang, J., and Wu, S.: Protein formulation. US Patent March 14,1996, US6267958 B1.
30. Andya, J. D., Hsu, C. C., and Shire, S. J. (2003), Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations, AAPS PharmSci. 5(2): E10.
31. Yang, M. X., Shenoy, B., Disttler, M., Patel, R., McGrath, M., Pechenov, S., and Margolin, A. L., (2003), Crystalline monoclonal antibodies for subcutaneous delivery, Proc. Natl. Acad. Sci. USA 100(12): 6934-6939.
32. Brange, J. and Vølund, A. (1999), Insulin analogs with improved pharmacokinetic profiles, Adv. Drug Deliv. Rev. 35(2-3): 307-335.
33. Harris, L. J., Skaletsky, E., and McPherson, A. (1995), Crystallization of intact monoclonal antibodies, Proteins 23(2): 285-289.
34. Shenoy, B., Wang, Y., Shan, W., and Margolin, A. L. (2001), Stability of crystalline proteins, Biotechnol. Bioeng. 73(5): 358-369.
35. Matheus, S., Friess, W., and Mahler, H. (2005), High Concentration IgG1-Antibody Formulations by Precipitation and Crystallisation, AAPS National Biotechnology Conf. poster, San Francisco.
36. Creighton, T. (1992), Proteins in solution and in membranes, in Proteins: Structures and Molecular Properties, 2nd ed., Freeman, New York, pp. 261-272.
37. Matheus, S., Mahler, H.-C. Solid forms of anti-EGFR antibodies. Patent US 2007/0122411 (A1), EP 1686961 (A1).
38. Jones, A. J. S. (1993), Analytical methods for the assessment of protein formulations and delivery systems, in Formulation and Delivery of Peptides and Proteins, Cleland, J. L. and Langer, R., eds., American Chemical Society, Washington, DC, pp. 22-45.
39. Pearlman, R. and Nguyen, T. H. (1991), Analysis of protein drugs, in Peptide and Protein Drug Delivery, Lee, V. H., ed., Marcel Dekker, New York, pp. 247-301.
40. Costantino, H. R., Chen, B., Griebenow, K., Hsu, C. C., and Shire, S. J. (1998), Fouriertransform infrared spectroscopic investigation of the secondary structure of aqueous and dried recombinant human deoxyribonuclease I, Pharm. Pharmacol. Commun. 4: 391-395.
41. Matheus, S., Friess, W., and Mahler, H. C. (2006), FTIR and nDSC as analytical tools for high-concentration protein formulations, Pharm. Res. 23(6): 1350-1363.
42. Prestrelski, S. J., Tedeschi, N., Arakawa, T., and Carpenter, J. F. (1993), Dehydrationinduced conformational transitions in proteins and their inhibition by stabilizers, Biophys. J. 65(2): 661-671.
43. Sharma, V. K., and Kalonia, D. S. (2003), Steady-state trytophan fluorescence spectroscopy study to probe tertiary structure of proteins in solid powders, J. Pharm. Sci. 92(4): 890-899.
44. Hatley, R. H. M. (1990), Proc. Int. Symp. Biological Product Freeze-Drying and Formulation, Bethesda, MD, pp. 105-122.
45. Breen, E. D., Curley, J. G., Overcashier, D. E., Hsu, C. C., and Shire, S. J. (2001), Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation, Pharm. Res. 18(9): 1345-1353.
46. McPhillips, C. D. Q. M., Royall, P. G., and Hill, V. L. (1999), Characterization of the glass transition of HPMC using modulated differential scanning calorimetry, Int. J. Pharm. 180: 83-90.
47. Georgalis, Y. and Saenger, W. (1999), Light scattering studies on supersaturated protein solutions, Sci. Progress 82(Pt. 4): 271-294.
48. Bloomfield, V. A. (1981), Quasi-elastic light scattering applications in biochemistry and biology, Annu. Rev. Biophys. Bioeng. 10: 421-450.
49. Pecora, R. (1972), Quasi-elastic light scattering from macromolecules, Annu. Rev. Biophys. Bioeng. 1: 257-276.
50. Schurr, J. M. (1977), Dynamic light scattering of biopolymers and biocolloids, CRC Crit. Rev. Biochem. 4(4): 371-431.
51. Wu, C. F. and Chen, S. H. (1988), Small angle neutron and x-ray scattering studies of concentrated protein solutions. II. Cytochrome C, Biopolymers 27(7): 1065-1083.
52. Schuck, P. (1998), Sedimentation analysis of noninteracting and self-associating solutes using numerical solutions to the Lamm equation, Biophys. J. 75(3): 1503-1512.
53. Johnson, M. L. and Straume, M. (1994), Comments on the analysis of sedimentation equilibrium experiments, in Modern Analytical Ultracentrifugation, Schuster, T. M. and Laue, T. M., eds., Birkhauser, Boston, pp. 37-63.
54. Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J., and Schubert, D. (2002), Sizedistribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems, Biophys. J. 82(2): 1096-1111.
55. Liu, J., Andya, J. D., and Shire, S. J. (2006), A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation, AAPS J. 8(3): E580-E589.
56. Gonzalez, J. M., Rivas, G., and Minton, A. P. (2003), Effect of large refractive index gradients on the performance of absorption optics in the Beckman XL-A/I analytical ultracentrifuge: An experimental study, Anal. Biochem. 313(1): 133-136.
57. Minton, A. P., and Lewis, M. S. (1981), Self-association in highly concentrated solutions of myoglobin: A novel analysis of sedimentation equilibrium of highly nonideal solutions, Biophys. Chem. 14(4): 317-324.
58. Minton, A. P. (1989), Analytical centrifugation with preparative ultracentrifuges, Anal. Biochem. 176: 209-216.
59. Moore, J., Kamerzell, T., Shen, Y., Kwong, Z., Zhu, Q., Laue, T., Liu, J., and Shire, S. (2007), High protein concentration analytical ultracentrifugation using fluorescence detection: Fluorescent labeling and characterization of monoclonal antibodies, Proc. AAPS Natl. Biotechnology Conf., San Diego.
60. Scherer, T., Kanai, S., Liu, J., and Shire, S. (2007). Characterization of monoclonal antibodies at high concentrations by light scattering, Proc. AAPS Natl. Biotechnology Conf., San Diego.
61. Kanai, S., Liu, J., Patapoff, T., and Shire, S. J. (2008), Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity, J. Pharm. Sci. 97(3): 4219-4227.
62. Saluja, A., Badkar, A. V., Zeng, D. L., Nema, S., and Kalonia, D. S. (2006), Application of high-frequency rheology measurements for analyzing protein-protein interactions in high protein concentration solutions using a model monoclonal antibody (IgG2), J. Pharm. Sci. 95(9): 1967-1983.
63. Hall, D. and Minton, A. P. (2003), Macromolecular crowding: Qualitative and semiquantitative successes, quantitative challenges, Biochim. Biophys. Acta 1649(2): 127-139.
64. Zimmerman, S. B. and Minton, A. P. (1993), Macromolecular crowding: Biochemical, biophysical, and physiological consequences, Annu. Rev. Biophys. Biomol. Struct. 22: 27-65.
65. Brange, J. (2000), Physical stability of proteins, in Pharmaceutical Formulation Development of Peptides and Proteins, Frokjaer, S. and Hovgaard, L., eds., Taylor & Francis, London, pp. 89-112.
66. Chi, E. Y., Krishnan, S., Randolph, T. W., and Carpenter, J. F. (2003), Physical stability of proteins in aqueous solution: Mechanism and driving forces in non-native protein aggregation, Pharm. Res. 20(9): 1325-1336.
67. Wang, W. (2005), Protein aggregation and its inhibition in biopharmaceutics, Int. J. Pharm. 289(1-2): 1-30.
68. Carpenter, J., Kendrick, B., Chang, B., Manning, M., and Randolph, T. (1999), Inhibition of stress induced aggregation of protein therapeutics, in Amyloid, Prions, and Other Protein Aggregates, Wetzel, R., ed., Academic Press, San Diego, pp. 236-255.
69. Dathe, M., Gast, K., Zirwer, D., Welfle, H., and Mehlis, B. (1990), Insulin aggregation in solution, Int. J. Pept. Protein Res. 36(4): 344-349.
70. Kendrick, B., Li, T., and Chang, B. (2003), Physical stabilization of proteins in aqueous solution, in Rational Design of Stable Protein Formualtions:Theory and Practice, Carpenter, J. and Manning, M., eds., Kluwer Academic/Plenum Publishers, New York, pp. 61-84.
71. Treuheit, M. J., Kosky, A. A., and Brems, D. N. (2002), Inverse relationship of protein concentration and aggregation, Pharm. Res. 19(4): 511-516.
72. Ahern, T. J. and Manning, M. C., eds. (1992), Stability of Protein Pharmaceuticals. Part A: Chemical and Physical Pathways of Protein Degradation, Plenum Press, New York, p. 434.
73. Cleland, J. L., Powell, M. F., and Shire, S. J. (1993), The development of stable protein formulations: A close look at protein aggregation, deamidation and oxidation, Crit. Rev. Ther. Drug Carrier Syst. 10(4): 307-377.
74. Manning, M. C., Patel, K., and Borchardt, R. T. (1989), Stability of protein pharmaceuticals, Pharm. Res. 6(11): 903-918.
75. Glatz, C. E. (1992), Modeling of aggregation-precipitation phenomena, in Stability of Protein Pharmaceuticals, Ahern, T. J. and Manning, M. C., eds., Plenum Press, New York, pp. 135-166.
76. Jones, L. S., Kaufmann, A., and Middaugh, C. R. (2005), Silicone oil induced aggregation of proteins, J. Pharm. Sci. 94(4): 918-927.
77. Chantelau, E. (1989), Silicone oil contamination of insulin, Diabet. Med. 6(3): 278.
78. Fraunhofer,W. andWinter, G. (2004), The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics, Eur. J. Pharm. Biopharm. 58(2): 369-383.
79. Rosenberg, A. (2006), Effects of protein aggregates: An immunologic perspective, AAPS J. 8(3): E59
80. Harrison, B. and Rios, M. (2007), Big shot-developments in prefilled syringes, Pharm. Technol. 31(3): 50-60.
81. Cantor, C. R. and Schimmel, P. R. (1980), Other hydrodynamic techniques, in Biophysical Chemistry Part II: Techniques for the Study of Biological Structure and Function, Cantor, C. and Schimmel, P., eds., Freeman, New York, pp. 643-685.
82. Harding, S. E. (1997), The intrinsic viscosity of biological macromolecules. Progress in measurement, interpretation and application to structure in dilute solution, Progress Biophys. Mol. Biol. 68(2-3): 207-262.
83. Ross, P. D. and Minton, A. P. (1977), Hard quasispherical model for the viscosity of hemoglobin solutions, Biochem. Biophys. Res. Commun. 76(4): 971-976.
84. Arvinte, T. and Fauquex, P. (2002), Stable Liquid Formulations. ed.
85. Basu, S. K., Govardhan, C. P., Jung, C. W., and Margolin, A. L. (2004), Protein crystals for the delivery of biopharmaceuticals, Expert Opin. Biol. Ther. 4(3): 301-317.
86. Akers, M., Vasudevan, V., and Stickelmeyer, M. (2002), Formulation development of protein dosage forms, in Development and Manufacture of Protein Pharmaceuticals, Nail, S. and Akers, M., eds., Springer, pp. 47-114.
87. Matheus, S., Friess, W., and Mahler, H. (2005), Liquid high concentration IgG1-antibody formulations, Proc. AAPS Natl. Biotechnology Conf., San Francisco.
88. Minton, A. P. and Edelhoch, H. (1982), Light scattering of bovine serum albumin solutions: Extension of the hard particle model to allow for electrostatic repulsion, Biopolymers 21(2): 451-458.
89. Burgess, D. J., Hussain, A. S., Ingallinera, T. S., and Chen, M.-L. (2002), Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP, Pharm. Res. 19(11): 1761-1768.
90. Allahham, A., Stewart, P., Marriott, J., and Mainwaring, D. E. (2004), Flow and injection characteristics of pharmaceutical parenteral formulations using a micro-capillary rheometer, Int. J. Pharm. 270(1-2): 139-148.
91. Zingerman, J., Pope, D.,Wilkinson, P., and Perfetto, L. (1987), Automatic injector apparatus for studying the injectability of parenteral formulations for animal health, Int. J. Pharm. 36(2-3): 141-145.
92. Ritschel, W. and Suzuki, K. (1979), In vitro testing of injectability, Pharm. Industr. 41: 468-475.